IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Pfizer (PFE) stock is in focus as the company and Astellas (ALPMF) post a late-stage trial win for their cancer drug Padcev ...

默克（Merck）周二宣布，其重磅免疫疗法Keytruda与辉瑞（Pfizer）的抗体药物偶联物Padcev联合疗法，在治疗一种膀胱癌方面显示出积极成果。

Merck has begun the 8% reduction of its workforce—an initiative that the company revealed two weeks ago—with the dismissal of ...

辉瑞（Pfizer）周二宣布，其抗体药物偶联物Padcev与默克（Merck）的免疫疗法Keytruda联合使用，在治疗一种膀胱癌方面显示出积极效果。 这家美国生物制药公司表示，一项III期试验表明，在接受治疗的患者中，无事件生存期（研究的主要终点）出现了“具有临床相关性和统计学意义的改善”。两项次要终点也取得进展，包括总生存期的改善，以及与单独手术相比，对于不适合化疗的浸润性膀胱癌（MIBC）患 ...

The rising bladder cancer star that is the combination of Pfizer and Astellas’ Padcev and Merck’s Keytruda is looking to set ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug Keytruda, the best-selling medicine in the world.

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.’s blockbuster ...

Merck said on Wednesday it will acquire UK-based Verona Pharma for about $10 billion, gaining a promising respiratory treatment as it faces pressure to diversify beyond its blockbuster cancer drug ...